- The brucellosis market, encompassing diagnostics, vaccines, and treatment solutions for both animal and human health, is increasingly recognized as a vital component of global public health and food safety systems. Its growth is driven by the zoonotic nature of the disease, its significant economic impact on livestock, and the growing emphasis on integrated disease control programs
- The escalating demand for effective brucellosis solutions is primarily fuelled by the widespread incidence of the disease in livestock populations, rising awareness among stakeholders about its impact on animal productivity and human health, and a growing preference for robust biosecurity measures. These converging factors are accelerating the uptake of brucellosis solutions, thereby significantly boosting the industry's growth
- North America dominated the brucellosis market with the largest revenue share of 35.4% in 2024. This is characterized by advanced animal health infrastructure, stringent regulatory frameworks for disease control, and a strong presence of key animal health companies
- Asia-Pacific is expected to be the fastest growing region in the brucellosis market during the forecast period, due to the vast livestock populations, increasing burden of the disease in many countries, and rising governmental investments in animal disease surveillance and control programs
- Medication segment dominated the brucellosis market, with a market share of 85.6% in 2024. This is driven by the established necessity of specific antibiotic regimens as the cornerstone of both human and animal brucellosis treatment, directly addressing the causative bacterial infection
